Sansure Biotech Inc.
Symbol: 688289.SS
SHH
20.62
CNYMarktpreis heute
31.0215
P/E-Verhältnis
0.0048
PEG-Verhältnis
11.83B
MRK Kapital
- 0.03%
DIV Rendite
Sansure Biotech Inc. (688289-SS) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4781.8 | 5663.8 | 4682.7 | |||||||
balance-sheet.row.short-term-investments | 0 | 548.3 | 2451.2 | 2046.5 | |||||||
balance-sheet.row.net-receivables | 0 | 732.8 | 1472.7 | 894.1 | |||||||
balance-sheet.row.inventory | 0 | 376.6 | 355.3 | 369.5 | |||||||
balance-sheet.row.other-current-assets | 0 | 58.4 | 33.6 | 20 | |||||||
balance-sheet.row.total-current-assets | 0 | 5949.6 | 7525.4 | 5966.2 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1055.2 | 785.3 | 481 | |||||||
balance-sheet.row.goodwill | 0 | 7.7 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 328 | 84.4 | 45.6 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 335.6 | 84.4 | 45.6 | |||||||
balance-sheet.row.long-term-investments | 0 | 974.3 | -1793.8 | -1533.2 | |||||||
balance-sheet.row.tax-assets | 0 | 73.8 | 69.6 | 25 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 65.6 | 2502.8 | 2105.8 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 2504.6 | 1648.3 | 1124.1 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.account-payables | 0 | 468.7 | 791.4 | 258.7 | |||||||
balance-sheet.row.short-term-debt | 0 | 77.2 | 14.3 | 8.5 | |||||||
balance-sheet.row.tax-payables | 0 | 17.7 | 216.4 | 101.3 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 18.2 | 13.6 | 6.4 | |||||||
Deferred Revenue Non Current | 0 | 32.5 | 30.5 | 25.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 340.5 | 712.9 | 2.4 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 77.7 | 89.3 | 45.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 18.2 | 13.6 | 6.4 | |||||||
balance-sheet.row.total-liab | 0 | 996.8 | 1661 | 709 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 588.5 | 588.5 | 400 | |||||||
balance-sheet.row.retained-earnings | 0 | 4882.7 | 5077.1 | 3820 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 395.2 | 377.4 | 294 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1334.9 | 1457.7 | 1854.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 7201.3 | 7500.6 | 6368.9 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.minority-interest | 0 | 223.6 | 12.2 | 12.4 | |||||||
balance-sheet.row.total-equity | 0 | 7424.9 | 7512.8 | 6381.3 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 1522.6 | 657.4 | 513.2 | |||||||
balance-sheet.row.total-debt | 0 | 95.4 | 27.9 | 14.9 | |||||||
balance-sheet.row.net-debt | 0 | -4138 | -3184.7 | -2621.3 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1936.7 | 2242.5 | 2616.6 | ||||||
cash-flows.row.depreciation-and-amortization | 0 | 89.1 | 53.9 | 26.7 | ||||||
cash-flows.row.deferred-income-tax | 0 | -40 | -8.1 | -4.6 | ||||||
cash-flows.row.stock-based-compensation | 0 | 60.8 | 5.6 | 4.6 | ||||||
cash-flows.row.change-in-working-capital | 0 | 203.3 | -402.1 | -50.4 | ||||||
cash-flows.row.account-receivables | 0 | -496.5 | -304.1 | -419.4 | ||||||
cash-flows.row.inventory | 0 | -282.1 | -93 | -212.1 | ||||||
cash-flows.row.account-payables | 0 | 496.5 | 3.1 | 585.7 | ||||||
cash-flows.row.other-working-capital | 0 | 485.4 | -8.1 | -4.6 | ||||||
cash-flows.row.other-non-cash-items | 0 | 308.9 | -14.8 | 49.4 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.acquisitions-net | 0 | -11.6 | 15.9 | 115 | ||||||
cash-flows.row.purchases-of-investments | 0 | -12140.6 | -7880 | -3725 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 11591.1 | 7125.6 | 2111.3 | ||||||
cash-flows.row.other-investing-activites | 0 | -46.9 | -0.9 | -108.7 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1166.7 | -1112.2 | -1716 | ||||||
cash-flows.row.debt-repayment | 0 | -17.2 | -55 | -55 | ||||||
cash-flows.row.common-stock-issued | 0 | 274.6 | 200 | 0 | ||||||
cash-flows.row.common-stock-repurchased | 0 | -257.4 | -200 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | -656.9 | -439.9 | -301.3 | ||||||
cash-flows.row.other-financing-activites | 0 | -259 | -193.7 | 1966.2 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -915.9 | -688.6 | 1609.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -10 | -34.3 | -44.6 | ||||||
cash-flows.row.net-change-in-cash | 0 | 466.2 | 42 | 2491.6 | ||||||
cash-flows.row.cash-at-end-of-period | 0 | 3099.1 | 2632.8 | 2590.8 | ||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2632.8 | 2590.8 | 99.2 | ||||||
cash-flows.row.operating-cash-flow | 0 | 2558.9 | 1877.1 | 2642.3 | ||||||
cash-flows.row.capital-expenditure | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.free-cash-flow | 0 | 2000.1 | 1504.2 | 2533.6 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1002.5 | 6450.4 | 4514.5 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 381.8 | 2655.4 | 1279 | |||||||
income-statement-row.row.gross-profit | 0 | 620.7 | 3795 | 3235.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.operating-expenses | 0 | 638.7 | 1262.2 | 666.9 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 1020.5 | 3917.5 | 1945.9 | |||||||
income-statement-row.row.interest-income | 0 | 54.7 | 48.4 | 32.5 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 136.8 | 290.8 | -20.7 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | -18 | 2339.8 | 2621.8 | |||||||
income-statement-row.row.income-before-tax | 0 | 432.6 | 2315.9 | 2616.2 | |||||||
income-statement-row.row.income-tax-expense | 0 | 62.3 | 379.2 | 373.7 | |||||||
income-statement-row.row.net-income | 0 | 363.7 | 1936.8 | 2242.7 |
Häufig gestellte Frage
Wie hoch ist die Sansure Biotech Inc. (688289.SS) Gesamtvermögen?
Sansure Biotech Inc. (688289.SS) Gesamtvermögen ist 8454204974.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.729.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.496.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.321.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.334.
Was ist der Sansure Biotech Inc. (688289.SS) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 363721131.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 95444005.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 638676546.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.